Liz Parrish, CEO of BioViva
Liz Parrish is the CEO and founder of BioViva, a biotechnology company developing treatments to slow the aging process in humans. Parrish's treatment often labeled as self-experimentation is highly controversial. As the requirements to progress to human trials had not started, the US Food and Drug Administration did not authorize Parrish's experiments. Parrish traveled to Colombia for the treatments.
BioViva was founded in 2015. In early 2016, Sierra Sciences announced that they were working with BioViva to start a new medical tourism-based venture, BioViva FIJI, on Fiji and that they will be the first company to use gene therapy to treat biological aging in humans. CEO Liz Parrish explained the reason for setting up in Fiji: "The current regulatory authorities have an outdated model that does not accommodate these new technologies." In June 2016, government sources in Fiji denied knowledge of the venture.
BioViva released data gathered post-therapy in 2016, claiming that independent testing by SpectraCell Laboratories had revealed Parrish's leukocyte telomere length had been extended from 6.71kb to 7.33kb, an amount they state is equivalent to a reversal of 20 years of telomere attrition. The company also released data suggesting an improvement in insulin sensitivity, an increase in muscle mass, a more favourable blood lipid profile and a reduction in C-reactive protein, a potent marker of inflammation.
BioViva's CEO Liz Parrish appeared on Norwegian television in the program Trygdekontoret to discuss the use of gene and cell therapies to improve health in an aging population. Parrish has also appeared on Australian network ABC's Lateline, discussing BioViva's development of therapies to treat biological aging.
Parrish appeared at WIRED Health 2017 in London to discuss BioViva's testing of gene therapies targeting hallmarks of the aging process. Appearing in WIRED, Parrish stated, "The company was built essentially to prove these therapies work or not. Remember BioViva is not a research organization. We are taking things like gene therapies and using them like technology."